Acadia Pharmaceuticals (ACAD) Minority Interest (2012 - 2013)
Acadia Pharmaceuticals' quarterly Minority Interest came in at $10.7 million in Q3 2013, down 39.64% quarter-over-quarter from $17.7 million in Q2 2013.
Acadia Pharmaceuticals has reported Minority Interest for 2 years, with the latest figure at $10.7 million in Q3 2013.
- For the quarter ending Q3 2013, Minority Interest changed N/A year-over-year to $10.7 million; the trailing twelve-month figure through Sep 2013 stood at $10.7 million (changed N/A YoY), and the FY2012 full-year result was $17.7 million, changed N/A from the prior year.
- Minority Interest for Q3 2013 stood at $10.7 million, down from $17.7 million in the prior quarter.
- The five-year high for Minority Interest was $17.7 million in Q4 2012, with the low at $10.7 million in Q3 2013.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Acadia Pharmaceuticals | 3.69 Bn | 2.84 Bn | 243.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2013 | 10.66 Mn |
| Jun 30, 2013 | 17.66 Mn |
| Mar 31, 2013 | 17.66 Mn |
| Dec 31, 2012 | 17.66 Mn |